450 Followers on Owler

Recipharm

Recipharm is a contract development and manufacturing organization specializing in pharmaceutical products. Read more

Marc Funk's photo - CEO of Recipharm

CEO

Marc Funk

CEO Approval Rating

82/100

Founded:

1995

Status:

PrivateAcquired by EQT Group

Est. Annual Revenue
Est. Employees
Sector

Update Industry

RECIPHARM TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

DPT Laboratories is one of Recipharm's top competitors. DPT Laboratories was founded in 1938 in San Antonio, Texas. DPT Laboratories operates in the Pharmaceuticals industry. DPT Laboratories generates $1.3B less revenue than Recipharm.

WellSpring Pharma Services, Inc. is a top competitor of Recipharm. WellSpring Pharma Services, Inc. was founded in 2001, and is headquartered in Oakville, Ontario. WellSpring Pharma Services, Inc. is in the Pharmaceuticals industry. WellSpring Pharma Services, Inc. generates $1.3B less revenue vs. Recipharm.

PharmaTech is seen as one of Recipharm's top competitors. PharmaTech is headquartered in Davie, Florida, and was founded in 2009. PharmaTech is in the Pharmaceuticals field. PharmaTech generates 1.65% the revenue of Recipharm.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Aesica Pharmaceuticals a competitor of Recipharm?

Recipharm Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Consort Medical Plc

Nov 2019

Source »
$649M
Consort Medical is a contract developer and manufacturer of drug delivery devices that include nasal inhalers and pharmaceutical compounds.

-

Sanofi CMO Business, Sanofi S.A.

Jun 2018

Source »
$60.1M
-

-

Pharmaceutical Businesses, Kemwell

Feb 2017

Source »
$118.5M
-

-

Kemwell’s Pharmaceutical Contract Development and Manufacturing (CDMO) Businesses, U.S. and Swedish Operations

Apr 2016

Source »
$205M
-
Mitim S.r.l.

Feb 2016

Source »
$75.5M
Mitim develops and manufactures beta lactams in dry sterile powder for injectable solutions, tablets and oral suspensions.

These are all the companies that Recipharm has acquired. Recipharm has acquired 9 companies and its latest acquisition was Consort Medical Plc in Nov 2019. Consort Medical is a contract developer and manufacturer of drug delivery devices that include nasal inhalers and pharmaceutical compounds.

Recipharm Funding History

Since Recipharm was founded in 1995, it has participated in 6 rounds of funding. In total Recipharm has raised $797.0M. Recipharm's last funding round was on May 2020 for a total of $51.1M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Post-IPO Debt
May 2020
$51.1M
-
Post-IPO Debt
May 2018
$58.9M
-
Post-IPO Equity
Jan 2016
$32M
-
Post-IPO Debt
Sep 2014
$210M

DNB Scandinavian

IPO
Apr 2014
$432.3M
-

Since Recipharm was founded in 1995, it has participated in 6 rounds of funding. In total Recipharm has raised $797.0M. Recipharm's last funding round was on May 2020 for a total of $51.1M

Recipharm Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

LIDDS engages in researching and developing medicines and drugs for the treatment of prostate cancer.
$500K
Dec 16, 2015
Unattributed
-
Pharmanest is developing pain relief formulations based on well-known active substances. 
$3.3M
Jul 08, 2015
Equity
-
Synthonics is a pharmaceutical firm focused on novel drug discovery and development. 
-
Apr 13, 2015
Equity
-

These are all the companies that Recipharm has invested in. Recipharm has invested 9 companies and its latest investment was Consort Medical Plc in Nov 2019. Consort Medical is a contract developer and manufacturer of drug delivery devices that include nasal inhalers and pharmaceutical compounds.

Recipharm News

February 12, 2021The Pharma Letter

BRIEF-EC clears the acquisition of joint control of Recipharm

The European Commission has approved, under the EU Merger Regulation, the acquisition of joint contro... See more »
February 8, 2021Contract Pharma

Recipharm and Medspray Complete Joint Venture

Aim to utilize novel softmist technology for pharmaceutical applications.... See more »
January 21, 2021Manufacturing Chemist

Recipharm and binx announce long-term supply agreement

Recipharm is a minority investor in binx health... See more »
January 21, 2021Contract Pharma

Recipharm Signs Manufacturing Deal with Enzymatica

Agreement will involve an additional Recipharm production site in Pianezza, Italy.... See more »
January 13, 2021Manufacturing Chemist

Recipharm signs manufacturing agreement with Enzymatica

ColdZyme is intended to treat and alleviate common cold and has already been launched in about 30 cou... See more »
January 7, 2021FiercePharma

Moderna teams with Sweden's Recipharm to rev up EU vaccine manufacturing

Moderna teams with Sweden's Recipharm to rev up EU vaccine manufacturing fkansteiner Thu, 01/07/2021 ... See more »
January 4, 2021Manufacturing Chemist

Recipharm and Moderna sign fill-finish agreement

Subject to regulatory approval of the vaccine in relevant countries outside of the US, supply is expe... See more »

Recipharm Press Releases

February 4, 2021Cision

Roar BidCo's outstanding public offer for Recipharm AB (publ) - Consent granted to correct error in the Convertible Bond Terms

On 14 December 2020, EQT IX1 ("EQT IX"), through Roar BidCo AB2 ("Roar BidCo"), announced a... See more »
February 1, 2021B3C Group

Recipharm and Medspray Launch Resyca Joint Venture to Exploit Novel Softmist Technology for Pharmaceutical Applications

ENSCHEDE, the Netherlands, February 01, 2021 / B3C newswire / -- Recipharm AB (publ) ("Recipharm"), a... See more »
January 11, 2021Cision

XS1496895753)

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED... See more »
January 11, 2021Cision

Recipharm has convened a bondholder meeting to correct the terms and conditions of its convertible bonds and announces date for a preliminary 2020 year-end report

FOR DISTRIBUTION ONLY OUTSIDE THE UNITED STATES TO PERSONS OTHER THAN "U.S. PERSONS" (AS DEFINED... See more »
October 13, 2020Cision

Recipharm invests EUR 2.6 million in Kaysersberg facility

Global contract development and manufacturing organisation (CDMO), Recipharm, has announced a EUR... See more »
August 13, 2020Presswire

Complete contents of Recipharm's Ashton-under Lyne pharmaceutical manufacturing facility under the hammer

Complete contents of Recipharm's Ashton-under Lyne pharmaceutical manufacturing facility under the ha... See more »
July 31, 2020Cision

Change in the total number of shares and votes in Recipharm AB (publ)

As of 31 July 2020, the total number of shares in Recipharm AB (publ) ("Recipharm") amounts to... See more »

Recipharm Videos

Social Media

Recipharm Headquarters

Drottninggatan 29

Stockholm, Stockholms län101 32

46-8-602-52-00

Driving Directions »

Trending Companies

Recipharm Summary

ABOUT

Overview

Recipharm is a contract development and manufacturing organization specializing in pharmaceutical products. Recipharm was founded in 1995. Recipharm's headquarters is located in Stockholm, Stockholms län, SE 101 32. It has raised 797.0M in 6 rounds. T...

CEO

Recipharm's CEO, Marc Funk, currently has an approval rating of 82%. Recipharm's primary competitors are DPT Laboratories, WellSpring Pharma Services, Inc. & PharmaTech.

Frequently Asked Questions about Recipharm

  1. When was Recipharm founded?

    Recipharm was founded in 1995
  2. Who is Recipharm's CEO?

    Recipharm's CEO is Marc Funk
  3. How much revenue does Recipharm generate?

    Recipharm generates $1.4B in revenue
  4. How much funding does Recipharm have?

    Recipharm has historically raised $797M in funding
  1. Where is Recipharm's headquarters?

    Recipharm's headquarters is in Stockholm Stockholms län, SE
  2. How many employees does Recipharm have?

    Recipharm has 7,857 employees
  3. Who are Recipharm's competitors?

    Recipharm's top competitors are DPT Laboratories, WellSpring Pharma Services, Inc., PharmaTech
  4. Who has Recipharm invested in?

    Recipharm's has invested in companies such as Liddspharma, Pharmanest, Synthonics